Currently, several PPAR agonists such as PPARα agonist Wy14643, and PPARβ/δ agonists GW501516, GW0742, and MBX-8025 have been reported to be used in the treatment of NAFLD in experimental and clinical studies and for developing dual and pan-PPAR agonists, and might have a broader and more efficacious therapeutic potential in the future [19]. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.